Research Topics
| A J AllenSummaryAffiliation: Eli Lilly and Company Country: USA Publications
| Collaborators
|
Detail Information
Publications
Commentary by a child psychiatrist in industry on the assessment of drug safetyAlbert J Allen
Eli Lilly Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
J Child Adolesc Psychopharmacol 17:288-91. 2007- Drug development process for a product with a primary pediatric indicationAlbert J Allen
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
J Clin Psychiatry 63:44-9. 2002.... - Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disordersA J Allen
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Neurology 65:1941-9. 2005..To test the hypothesis that atomoxetine does not significantly worsen tic severity relative to placebo in children and adolescents with attention deficit/hyperactivity disorder (ADHD) and comorbid tic disorders... - Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy studyHumberto Quintana
Department of Psychiatry, Louisiana State University Health Sciences Center, New Orleans, Louisiana 70112, USA
Clin Ther 29:1168-77. 2007..Recently developed nonpsychostimulant treatments have allowed certain patients to switch from a psychostimulant to a nonpsychostimulant. However, the outcomes of such switches have not been systematically studied... - High-dose atomoxetine treatment of ADHD in youths with limited response to standard dosesChristopher J Kratochvil
University of Nebraska Medical Center, Omaha, NE 68198, USA
J Am Acad Child Adolesc Psychiatry 46:1128-37. 2007..To assess the utility and tolerability of higher than standard atomoxetine doses to treat attention-deficit/hyperactivity disorder (ADHD)... - Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depressionMark E Bangs
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA
J Child Adolesc Psychopharmacol 17:407-20. 2007..ATX was an effective and safe treatment for ADHD in adolescents with ADHD and MDD. However, this trial showed no evidence for ATX of efficacy in treating MDD... - A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorderSusan S F Gau
Department of Psychiatry, College of Medicine, National Taiwan Universiy, Taipei, Taiwan
J Child Adolesc Psychopharmacol 17:447-60. 2007..The aim of this study was to assess the efficacy and safety of the once-daily atomoxetine compared with placebo in pediatric patients with attention-deficit/hyperactivity disorder (ADHD) in Taiwan... - Atomoxetine treatment of ADHD in children with comorbid Tourette syndromeThomas J Spencer
Pediatric Psychopharmacology, Massachusetts General Hospital, Boston, MA 02114 2696, USA
J Atten Disord 11:470-81. 2008..This study examines changes in severity of tics and ADHD during atomoxetine treatment in ADHD patients with Tourette syndrome (TS)... - Functional outcomes in the treatment of adults with ADHDLenard A Adler
Department of Psychiatry, New York University School of Medicine, New York, NY 10010, USA
J Atten Disord 11:720-7. 2008..ADHD is associated with significant functional impairment in adults. The present study examined functional outcomes following 6-month double-blind treatment with either atomoxetine or placebo... - Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatmentThomas J Spencer
Massachusetts General Hospital Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
J Child Adolesc Psychopharmacol 17:689-700. 2007..To examine the effects on growth of long-term pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD), we present findings from an ongoing 5-year study of the efficacy and safety of treatment with atomoxetine... - Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placeboSitra Tauscher Wisniewski
Neuroscience, Eli Lilly and Company, Indianapolis, IN 46285, USA
J Child Adolesc Psychopharmacol 17:713-8. 2007..1% of placebo-treated patients (p = 0.588). This analysis fails to support an association between fluoxetine treatment and increased risk of aggression and/or hostility-related events in children and adolescents compared with placebo... 
Meta-analysis of suicide-related behavior events in patients treated with atomoxetineMark E Bangs
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
J Am Acad Child Adolesc Psychiatry 47:209-18. 2008..The present work examined suicide-related events in acute, double-blind, and placebo- or active comparator-controlled trials with atomoxetine...- Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential responseJeffrey H Newcorn
Department of Psychiatry, Mount Sinai Medical Center, Box 1230, One Gustave L Levy Place, New York, NY 10029, USA
Am J Psychiatry 165:721-30. 2008.... - Latino versus Caucasian response to atomoxetine in attention-deficit/hyperactivity disorderJorge M Tamayo
Department of Psychiatry, CES University, Medellin, Colombia
J Child Adolesc Psychopharmacol 18:44-53. 2008..We found that Latino and Caucasian children with attention-deficit/hyperactivity disorder (ADHD) exhibit a similar pattern of efficacy and tolerability with atomoxetine. The lack of placebo controls was a limitation of this study... - Abuse liability assessment of atomoxetine in a drug-abusing populationDonald R Jasinski
Johns Hopkins School of Medicine, Center for Chemical Dependence, 4940 Eastern Avenue, Baltimore, MD 21224, USA
Drug Alcohol Depend 95:140-6. 2008..This study assessed the abuse potential of atomoxetine in stimulant-preferring drug abusers compared to methylphenidate and phentermine as positive controls and desipramine and placebo as negative controls... - Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled studyDavid Michelson
Lilly Research Laboratories, Indianapolis, IN 46285, USA
Am J Psychiatry 159:1896-901. 2002..The authors assessed the efficacy of once-daily atomoxetine administration in the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD)... - Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetineJoachim F Wernicke
Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN, USA
Dev Med Child Neurol 49:498-502. 2007..The shared vulnerability between ADHD and seizure activity should be taken into account when making treatment decisions for populations of children with epilepsy and children with ADHD... - Effects of atomoxetine and methylphenidate on sleep in children with ADHDR Bart Sangal
Clinical Neurophysiology Services, PC, Troy, MI, USA
Sleep 29:1573-85. 2006..Although both medications decreased nighttime awakenings, the decrease was greater for methylphenidate... - Atomoxetine in adults with ADHD: two randomized, placebo-controlled studiesDavid Michelson
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
Biol Psychiatry 53:112-20. 2003..CONCLUSION: Atomoxetine appears to be an efficacious treatment for adult ADHD. Its lack of abuse potential may be an advantage for many patients... - Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessmentJoachim F Wernicke
Lilly Research Laboratories, Indianapolis IN 46285, USA
J Clin Psychopharmacol 24:30-5. 2004..It appears that atomoxetine may be discontinued without risk for symptom rebound or discontinuation-emergent adverse effects. Tapering of doses is not necessary when atomoxetine is discontinued... - Prevalence of obsessive-compulsive disorder in patients with systemic lupus erythematosusMarcia J Slattery
National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
J Clin Psychiatry 65:301-6. 2004..The goal of this pilot study was to investigate the prevalence of obsessive-compulsive disorder (OCD) in a group of patients with systemic lupus erythematosus (SLE)... - Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trialDouglas K Kelsey
Lilly Research Laboratories, Indianapolis, Indiana, USA
Pediatrics 114:e1-8. 2004..Another goal was to determine how early in treatment it was possible to discern a specific effect of the drug on ADHD symptoms... - Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorderMark E Bangs
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA
Drug Saf 31:345-54. 2008..This study describes and assesses potential hepatobiliary events related to atomoxetine therapy, as reported in clinical trials and as spontaneous adverse event reports post-launch in 2002... - A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHDMargaret Weiss
University of British Columbia, Vancouver, Canada
J Am Acad Child Adolesc Psychiatry 44:647-55. 2005.... - Safety and tolerability of once versus twice daily atomoxetine in adults with ADHDLenard Adler
School of Medicine, New York University, New York, NY, USA
Ann Clin Psychiatry 18:107-13. 2006..Changes in dosing strategy are unlikely to be accompanied by safety risks, implying that there is room for prescribers to use discretion and to base dosing strategies on individual factors... - Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHDJohn Polzer
Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
Biol Psychiatry 61:713-9. 2007..We systematically examined potential aggression/hostility-related events in a meta-analysis of acute clinical trials of atomoxetine for attention-deficit/hyperactivity disorder (ADHD)... - Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorderJeffrey H Newcorn
Mount Sinai Medical Center, Department of Psychiatry, One Gustave L Levy Place, Box 1230, New York, NY 10029, USA
Pediatrics 118:e1701-6. 2006..However, lower doses could be effective during maintenance treatment, which would reduce drug exposure and potential problems related to tolerability during chronic treatment... - Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetineLenard A Adler
Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA
J Clin Psychopharmacol 26:648-52. 2006..Despite the existence of research demonstrating the effects of ADHD on certain aspects of life, the clinical trials of treatments for this disorder have focused primarily on efficacy and safety... - Atomoxetine in the treatment of patients with ADHDJan A Gerbers
Am Fam Physician 71:1879-80; author reply 1880, 1882. 2005 - Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetineAmy R Perwien
Outcomes Research, US Medical Division, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
J Dev Behav Pediatr 25:264-71. 2004..Findings demonstrate the positive impact of atomoxetine on HRQL in children with ADHD... - Atomoxetine and tics in ADHDPeter D Feldman
J Am Acad Child Adolesc Psychiatry 44:405-6. 2005